Overview
Pharmaceutical

Kringle Pharma,Inc.

Kringle Pharma is a late-stage regenerative medicine biopharmaceutical venture focused on developing recombinant human HGF (Hepatocyte Growth Factor) protein therapeutics for intractable and rare diseases. The company has established a proprietary pharmaceutical-grade manufacturing platform for recombinant HGF protein and is conducting multiple clinical trials targeting conditions including acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. Its business model combines self-commercialization with sales partnerships (e.g., Maruishi Pharmaceutical) and active pharmaceutical ingredient supply to overseas partners such as Claris Biotherapeutics.

Market Cap
¥5.12B
US$32.7M
EV
¥3.43B
US$21.8M
Stock¥611▲+0.16%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
—
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
4.2
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▲+14.5%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Aug 12, 26Q3 earnings: Revenue +501% YoY, operating loss narrowed to ¥633M (from ¥738M)
MC → EV Bridge
5.12BUS$32.7MMarket Cap0.00BUS$0.00M+ Debt1.70BUS$10.8M− Cash0.00BUS$0.00M− Inv. Sec.3.43BUS$21.8MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.29US$1.85M'21/90.39US$2.49M'22/90.07US$0.44M'23/90.08US$0.51M'24/90.07US$0.46M'25/9
Net Income 5Y (¥B)
-0.30-US$1.92M'21/9-0.33-US$2.11M'22/9-0.85-US$5.45M'23/9-0.76-US$4.82M'24/9-0.92-US$5.84M'25/9
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
2.14US$13.6M'21/92.76US$17.6M'22/92.14US$13.6M'23/92.31US$14.8M'24/91.62US$10.3M'25/9
Shareholders
Top 10 hold 24.8%
1
Nippon Zenyaku Kogyo Co., Ltd.
6.77%
2
STATE STREET BANK AND TRUST COMPANY (Standing Proxy: Mizuho Bank, Ltd.)
3.07%
3
CYBERDYNE,INC.
2.70%
4
Nomura Securities Co., Ltd.
2.43%
5
Tetsuo YAMADA
2.40%
6
Jiro TAKAYAMA
1.63%
7
Ueda Yagi Tanshi Co., Ltd.
1.51%
8
Kiichi ADACHI
1.47%
9
Sadayuki MIWA
1.41%
10
Hitoshi MIYASAKA
1.39%
Management
10 officers
Kiichi ADACHI
Representative Director, President
May 1996 Postdoctoral Research Associate, Purdue University, IN, U.S.A. Mar 1999 Research Scientist, Paradigm Genetics, Inc., NC, U.S.A. Sep 2002 Joined Mitsui & Co. Strategic Research Institute, Biotechnology Center, as Chief Researcher Apr 2004 Joined the Company, General Manager, Research and Development Department Dec 2004 Director, General Manager, Research and Development Department, the Company Dec 2005 Director, Vice President, the Company Dec 2010 Director, General Manager, Business Development Department, the Company Apr 2011 Invited Associate Professor, Osaka University Dec 2016 Representative Director, President, the Company (current)
1967-02-27
Koichi MURAKAMI
Director, General Manager of Management Administration Department
Apr 1983 Joined Nihon Recruit Center Co., Ltd. (now Recruit Co., Ltd.) Oct 1992 Joined Flex Co., Ltd., Director Nov 2000 Joined Advanced Create Co., Ltd. Feb 2002 Director, General Manager of Business Planning Office, Advanced Create Co., Ltd. Oct 2007 Managing Executive Officer, General Manager of Management Division, Advanced Create Co., Ltd. Oct 2011 Director, Managing Executive Officer, General Manager of IT Division, Advanced Create Co., Ltd. Dec 2014 Director, Senior Executive Officer, General Manager of Internal Audit Office, Advanced Create Co., Ltd. Oct 2015 Director, Managing Executive Officer, General Manager of Compliance Division, Advanced Create Co., Ltd. Dec 2017 Senior Managing Director, General Manager of Management Division, Advanced Create Co., Ltd. Dec 2019 Joined Etvos Co., Ltd., Executive Officer, General Manager of Administration Department Aug 2020 Joined NHS Insurance Group Co., Ltd., Executive Officer, CFO Dec 2021 Joined the Company, Director, General Manager of Management Administration Department (current) Dec 2025 Joined Advanced Create Co., Ltd., Director (part-time) (current)
1960-02-11
Hiromasa HAYATA
Director, General Manager of Pharmaceutical Development Department and General Manager of Regulatory Affairs Department
May 2004 Joined the Company, Researcher, Research and Development Department Dec 2016 Manager, Pharmaceutical Development Department, the Company Jan 2018 Senior Manager, Pharmaceutical Development Department, the Company Jun 2021 General Manager, Pharmaceutical Development Department, the Company Dec 2022 Director, General Manager, Pharmaceutical Development Department, the Company Aug 2023 Director, General Manager, Pharmaceutical Development Department and General Manager, Regulatory Affairs Department, the Company (current)
1975-06-03
Yoshiyuki KAYANO
Director, General Manager of Reliability Assurance Department
Apr 2004 Joined Wakenyaku Co., Ltd. Oct 2005 Joined the Company, Researcher, Research and Development Department Jan 2011 Joined Okayama Taiho Pharmaceutical Co., Ltd. Apr 2019 Joined the Company, Manager, Pharmaceutical Development Department Jun 2021 Senior Manager, Pharmaceutical Development Department, the Company Jan 2023 General Manager, Reliability Assurance Department, the Company Dec 2023 Director, General Manager, Reliability Assurance Department, the Company (current)
1980-02-01
Masahiro TOMOYASU
Director
Apr 1995 Joined Snow Brand Milk Products Co., Ltd. (now Snow Brand Megmilk Co., Ltd.) Mar 2001 Joined Chugai Pharmaceutical Co., Ltd. Apr 2005 Joined UFJ Capital Co., Ltd. (now MUFG Capital Co., Ltd.) Sep 2015 Fellow, Anicom Capital Co., Ltd.; Established Tomoyasu Research Institute Co., Ltd., Representative Director (current) Jan 2016 Director, Kinopharma, Inc. (current) Sep 2016 Director, Anicom Capital Co., Ltd. Dec 2016 Director, the Company (current) Apr 2017 Part-time Lecturer, Department of Genome Medical Science, Saitama Medical University (current) Jul 2018 Outside Director, GenAhead Bio, Inc. (current) Dec 2020 Outside Director, Pharmabio Co., Ltd. (current) Mar 2022 Outside Director, Biomatrix Research Institute Co., Ltd. (current)
1970-07-28
Koichiro YOSHINO
Director
Apr 1974 Joined Kanebo, Ltd. Apr 1999 Joined Japan Organon Ltd., Director of Pharmaceutical Research Institute Apr 2003 Representative Director, President, Carna Biosciences, Inc. (current) Apr 2004 Visiting Professor, Center for Advanced Science and Innovation, Osaka University Mar 2011 President & CEO, CarnaBio USA, Inc. Oct 2013 Representative Director, President, ProbeX Inc. (now Carna Biosciences, Inc.) Dec 2018 Outside Director, Medinet Co., Ltd. (current) Dec 2018 Outside Director, the Company (current)
1949-03-25
Makoto FUKUI
Director
Apr 2004 Postdoctoral Research Associate, Duke University Medical Center, NC, U.S.A. Apr 2007 Joined Nippon Zenyaku Kogyo Co., Ltd. Apr 2009 Director, Central Research Institute, Nippon Zenyaku Kogyo Co., Ltd. Dec 2012 Research Associate, Fellowship Program, University of California, Davis, Veterinary Medical Center, San Diego / University of California, San Diego, School of Medicine, CA, U.S.A. May 2015 Director, Xenoac Resource Co., Ltd. (now Xenogen Pharma Co., Ltd.) May 2018 Senior Managing Director, Xenoac Resource Co., Ltd.; Director, Nippon Zenyaku Kogyo Co., Ltd. Dec 2020 Outside Director, the Company (current) Jul 2021 Representative Director, President, Xenogen Pharma Co., Ltd. (current) Jun 2025 Director, Xenoac Holdings Co., Ltd. (current)
1976-11-24
Naomi DOI
Full-time Audit & Supervisory Board Member
Mar 1990 Completed Doctoral Program, Graduate School of Science, Kyushu University Apr 1990 Joined Kaken Pharmaceutical Co., Ltd., Pharmacology Research Department, Central Research Laboratories Feb 1996 Postdoctoral Research Associate, University of Edinburgh Medical School, U.K. (seconded from Kaken Pharmaceutical Co., Ltd.) Feb 1998 Pharmacology Research Department, General Research Institute, Kaken Pharmaceutical Co., Ltd. Apr 2010 General Manager, R&D Operations Management Center, Kaken Pharmaceutical Co., Ltd. Apr 2012 General Manager, Reliability Assurance Department, Kaken Pharmaceutical Co., Ltd. Jun 2018 Full-time Audit & Supervisory Board Member, Kaken Pharmaceutical Co., Ltd. Jun 2023 Management Advisor (part-time), Kaken Pharmaceutical Co., Ltd. (current) Dec 2023 Outside Audit & Supervisory Board Member (part-time), CellAxia Inc. (current) Dec 2024 Outside Audit & Supervisory Board Member, the Company (current)
1958-11-14
Masahiro MOTOKAWA
Audit & Supervisory Board Member
Nov 2003 Joined BearingPoint Co., Ltd. Jun 2006 Joined Azusa Audit Corporation (now Azusa Audit LLC) Aug 2018 Head, D&A Sogo Accounting Office (current) Aug 2018 Designated Partner, Shingetsu LLC Audit Corporation (current) Dec 2018 Outside Audit & Supervisory Board Member, the Company (current) Dec 2021 Outside Audit & Supervisory Board Member, Doctors Mobile Inc. Nov 2023 Outside Audit & Supervisory Board Member, Rivascular Bio Inc. (current)
1974-01-22
Yosuke YAMAGUCHI
Audit & Supervisory Board Member
Sep 2007 Joined Kitahama Law Offices, Gaikokuho Joint Enterprise Jul 2011 Seconded to Osaka Securities Exchange Co., Ltd. (now Japan Exchange Regulation) Aug 2016 Co-Partner, Iwatani Muramoto Yamaguchi Law Office (current) Dec 2018 Outside Audit & Supervisory Board Member, the Company (current) Apr 2020 Outside Audit & Supervisory Board Member, akippa Inc. (current) Dec 2021 Outside Audit & Supervisory Board Member, Fit Crew Inc. Jul 2022 Outside Audit & Supervisory Board Member, Center Mobile Inc.
1979-03-26
Large Shareholding Reports
Evo Fund
2026-08-27
6.01%→4.79%
Evo Fund
2026-06-05
6.17%→6.01%
Evo Fund
2026-05-29
7.39%→6.17%
Evo Fund
2026-05-25
8.45%→7.39%
Evo Fund
2026-05-25
9.56%→8.45%
Correction filing (name/detail fix only) — ratio carried over from the original filing
Evo Fund
2026-05-20
9.56%→8.45%
Evo Fund
2026-04-09
13.20%→9.56%
Evo Fund
2026-04-08
17.55%→13.20%
Evo Fund
2026-03-18
18.65%→17.55%
Evo Fund
2025-12-03
20.07%→18.65%
Evo Fund
2025-10-16
20.32%→20.07%
Evo Fund
2025-10-15
21.50%→20.32%
Evo Fund
2025-09-24
22.48%→21.50%
Evo Fund
2025-08-22
23.51%→22.48%
Evo Fund
2025-08-08
23.51%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-27
Large Shareholding Report
TDnet
2026-08-10
Q3 Earnings Flash
FY ending Sep 2026
EDINET
2026-06-05
Large Shareholding Report
EDINET
2026-05-29
Large Shareholding Report
EDINETAmended
2026-05-25
Change Report
EDINET
2026-05-25
Large Shareholding Report
EDINET
2026-05-20
Large Shareholding Report
EDINET
2026-05-11
Semi-Annual Securities Report
Period: Oct 2025 – Sep 2026
EDINET
2026-04-09
Large Shareholding Report
EDINET
2026-04-08
Large Shareholding Report
EDINET
2026-03-18
Large Shareholding Report
TDnet
2026-02-09
Q1 Earnings Flash
FY ending Sep 2026
EDINET
2025-12-19
Annual Securities Report
Period: Oct 2024 – Sep 2025
EDINET
2025-12-03
Large Shareholding Report
EDINET
2025-10-16
Large Shareholding Report
EDINET
2025-10-15
Large Shareholding Report
EDINET
2025-09-24
Large Shareholding Report
EDINET
2025-08-22
Large Shareholding Report
EDINET
2025-08-08
Large Shareholding Report
TDnet
2025-08-08
Q3 Earnings Flash
FY ending Sep 2025
EDINET
2025-07-16
Securities Registration Statement
EDINET
2025-05-12
Semi-Annual Securities Report
Period: Oct 2024 – Sep 2025
TDnet
2025-02-07
Q1 Earnings Flash
FY ending Sep 2025
EDINET
2024-12-23
Annual Securities Report
Period: Oct 2023 – Sep 2024
EDINET
2024-05-13
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-02-09
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-12-25
Annual Securities Report
Period: Oct 2022 – Sep 2023
EDINETAmended
2023-08-23
Amended Securities Registration Statement
EDINETAmended
2023-08-18
Amended Securities Registration Statement
EDINET
2023-08-14
Securities Registration Statement
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →